0

Blog

Showing 4 of 4 articles
LEGAL
Paradigm Peptides got the opposite kind of result.
September 3, 2026 · LEGAL

Paradigm Peptides got the opposite kind of result.

Paradigm owner Matthew Kawa was sentenced on July 30 to five years and ten months in federal prison. Employee Jennifer…

Read article
ELORA
Eloralintide found a second engine.
September 3, 2026 · ELORA

Eloralintide found a second engine.

Eloralintide is Lilly’s weekly amylin agonist. Its standalone Phase 2 trial showed up to 20.1% mean weight loss at 48…

Read article
RETA
Retatrutide added two more Phase 3 wins.
September 3, 2026 · RETA

Retatrutide added two more Phase 3 wins.

Lilly’s TRIUMPH-2 enrolled 1,152 adults with obesity or overweight and type 2 diabetes. At 80 weeks, the 12 mg group…

Read article
Compliance & Compounding
the room said yes. the rulebook has not moved yet.
August 31, 2026 · Compliance & Compounding

the room said yes. the rulebook has not moved yet.

On July 23 and 24, the Pharmacy Compounding Advisory Committee, or PCAC, considered whether seven peptide families should be eligible…

Read article
Stay in the loop

New compounds, COAs and
offers — first.

Join the list for early access to new batches and research resources. No spam, unsubscribe anytime.